Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10504)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Feb 15, 2015 (publication date) through Jun 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ohkura T. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes 2015; 6(1): 136-144 [PMID: 25685284 DOI: 10.4239/wjd.v6.i1.136] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v6/i1/136.htm |
| Number | Citing Articles |
| 1 |
Shuai Ma, Zhenren Liu, Jing Pan, Shunli Zhang, Weicheng Zhou. A concise and practical stereoselective synthesis of ipragliflozin L-proline. Beilstein Journal of Organic Chemistry 2017; 13: 1064 doi: 10.3762/bjoc.13.105
|
| 2 |
Yoshio Nagai, Akio Ohta, Yukiyoshi Sada, Hiroyuki Kato, Yasushi Tanaka. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 2017; 18(1): 13 doi: 10.1080/14656566.2016.1261110
|
| 3 |
Atsushi Tanaka, Toyoaki Murohara, Isao Taguchi, Kazuo Eguchi, Makoto Suzuki, Masafumi Kitakaze, Yasunori Sato, Tomoko Ishizu, Yukihito Higashi, Hirotsugu Yamada, Mamoru Nanasato, Michio Shimabukuro, Hiroki Teragawa, Shinichiro Ueda, Satoshi Kodera, Munehide Matsuhisa, Toshiaki Kadokami, Kazuomi Kario, Yoshihiko Nishio, Teruo Inoue, Koji Maemura, Jun-ichi Oyama, Mitsuru Ohishi, Masataka Sata, Hirofumi Tomiyama, Koichi Node. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovascular Diabetology 2016; 15(1) doi: 10.1186/s12933-016-0449-7
|
| 4 |
Sanjay Kalra, Kimi K. Shetty, Vertivel B. Nagarajan, Jignesh K. Ved. Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update. Diabetes Therapy 2020; 11(4): 813 doi: 10.1007/s13300-020-00789-y
|
| 5 |
Hotimah Masdan Salim, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro, Masataka Sata. Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. Frontiers in Cardiovascular Medicine 2016; 3 doi: 10.3389/fcvm.2016.00043
|
| 6 |
Tsuyoshi Okura, Yohei Fujioka, Risa Nakamura, Sonoko Kitao, Yuichi Ito, Mari Anno, Kazuhisa Matsumoto, Kyoko Shoji, Kazuhiko Matsuzawa, Shoichiro Izawa, Hiroko Okura, Etsuko Ueta, Masahiko Kato, Takeshi Imamura, Shin-ichi Taniguchi, Kazuhiro Yamamoto. The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-05704-y
|
| 7 |
A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin. Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice 2021; (5): 50 doi: 10.37489/2588-0519-2020-5-50-63
|
| 8 |
Shubham Batra, Prabhjeet Kaur Bamrah, Manjusha Choudhary. Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds. Egyptian Journal of Basic and Applied Sciences 2023; 10(1): 69 doi: 10.1080/2314808X.2022.2145734
|
| 9 |
Yuka Ito, Kaori Ambe, Toshiki Hayase, Mayu Kobayashi, Masahiro Tohkin. Comparison of Efficacy of Dipeptidyl Peptidase‐4 Inhibitors and Sodium‐Glucose Co‐Transporter 2 Inhibitors Between Japanese and Non‐Japanese Patients: A Meta‐Analysis. Clinical and Translational Science 2020; 13(3): 498 doi: 10.1111/cts.12732
|
| 10 |
Minju Park, Seo-Yeong Mun, Wenwen Zhuang, Junsu Jeong, Hye Ryung Kim, Hongzoo Park, Eun-Taek Han, Jin-Hee Han, Wanjoo Chun, Hongliang Li, Won Sun Park. The antidiabetic drug ipragliflozin induces vasorelaxation of rabbit femoral artery by activating a Kv channel, the SERCA pump, and the PKA signaling pathway. European Journal of Pharmacology 2024; 972: 176589 doi: 10.1016/j.ejphar.2024.176589
|
| 11 |
Atsuo Tahara, Toshiyuki Takasu. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. Naunyn-Schmiedeberg's Archives of Pharmacology 2018; 391(4): 395 doi: 10.1007/s00210-018-1469-5
|
| 12 |
Prerna Ganwir, Rajendra Bhadane, Ganesh U. Chaturbhuj. In-silico screening and identification of glycomimetic as potential human sodium-glucose co-transporter 2 inhibitor. Computational Biology and Chemistry 2024; 110: 108074 doi: 10.1016/j.compbiolchem.2024.108074
|
| 13 |
Mitsutoshi Kato, Kumiko Sakai, Kyoko Saito, Kensuke Tsutsui, Shigeo Yamashita, Noriko Kato. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin. Diabetology International 2017; 8(3): 275 doi: 10.1007/s13340-017-0307-1
|
| 14 |
K. Pafili, E. Maltezos, N. Papanas. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. Expert Opinion on Investigational Drugs 2016; 25(10): 1133 doi: 10.1080/13543784.2016.1216970
|
| 15 |
Adel Galal El-Shemi, Osama Adnan Kensara, Aiman Alsaegh, Mohammed Hasan Mukhtar. Pharmacotherapy with Thymoquinone Improved Pancreatic β-Cell Integrity and Functional Activity, Enhanced Islets Revascularization, and Alleviated Metabolic and Hepato-Renal Disturbances in Streptozotocin-Induced Diabetes in Rats. Pharmacology 2018; 101(1-2): 9 doi: 10.1159/000480018
|
| 16 |
Min-Koo Choi, So Jeong Nam, Hye-Young Ji, Mi Jie Park, Ji-Soo Choi, Im-Sook Song. Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin. Pharmaceutics 2020; 12(3): 268 doi: 10.3390/pharmaceutics12030268
|
| 17 |
Weiping Chen, Pengyun Li, Guoqi Wang, Yang Chen, Bin Wang, Mulan Chen. Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials. Postgraduate Medicine 2019; 131(8): 578 doi: 10.1080/00325481.2019.1655381
|
| 18 |
Prabhsimran Kaur, Bidwan Sekhar Behera, Sandeep Singh, Anjana Munshi. “The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics”. European Journal of Pharmacology 2021; 904: 174169 doi: 10.1016/j.ejphar.2021.174169
|
| 19 |
Ernest Adeghate, Sahar Mohsin, Faisal Adi, Fares Ahmed, Ali Yahya, Huba Kalász, Kornelia Tekes, Ernest A. Adeghate. An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials. Expert Opinion on Investigational Drugs 2019; 28(9): 811 doi: 10.1080/13543784.2019.1655539
|
| 20 |
Eva Y Wong. A Review of Sodium Glucose Co transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus. Pharmacy & Pharmacology International Journal 2016; 4(2) doi: 10.15406/ppij.2016.04.00070
|